Literature DB >> 35064299

Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy.

Kosuke Ozaki1,2, Kazushige Kawai3, Hiroaki Nozawa3, Kazuhito Sasaki3, Koji Murono3, Shigenobu Emoto3, Hiroyuki Abe4, Tetsuo Ushiku4, Soichiro Ishihara3.   

Abstract

PURPOSE: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME) without lateral lymph node (LLN) dissection is widely performed for lower advanced rectal cancer. However, it is unclear whether residual cancer cells in the LLNs undergo apoptosis, disappear, or regrow if unresected.
METHODS: Overall, 293 consecutive patients with T3/4 rectal cancer who underwent CRT followed by radical surgery between September 2003 and December 2018 were retrospectively reviewed. We assessed apoptosis of the residual primary tumor, mesorectum lymph nodes (MLN), and LLN using M30 cytoDEATH immunostaining and evaluated the degree of apoptosis. The difference in the prognosis of the lateral lymph node metastasis positive (LLNM +) and lateral lymph node metastasis negative (LLNM-) groups was assessed.
RESULTS: There were 31 patients (10.6%) who were diagnosed with a complete response by hematoxylin and eosin (HE) staining. The residual cancer cells showed complete apoptosis in the primary lesion in 28 patients, in the metastatic MLN in only two patients, and in the metastatic LLN in one patient. The LLNM + group had a significantly poorer distant recurrence, recurrence-free survival, and overall survival than the LLNM- group.
CONCLUSION: The majority of the residual cancer tissue in LNs observed by HE staining was found to be non-apoptotic. If LLN metastasis is suspected on pretreatment imaging, performing LLN dissection together with TME should be considered.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chemoradiotherapy; Lateral lymph node metastasis; Rectal cancer

Mesh:

Year:  2022        PMID: 35064299     DOI: 10.1007/s00384-021-04085-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  20 in total

Review 1.  Lateral node dissection and total mesorectal excision for rectal cancer.

Authors:  T Takahashi; M Ueno; K Azekura; H Ohta
Journal:  Dis Colon Rectum       Date:  2000-10       Impact factor: 4.585

2.  Development of a novel apoptosis-based tumor regression grade to assess the efficacy of preoperative chemoradiotherapy for rectal cancer: a retrospective single-center study.

Authors:  Kosuke Ozaki; Kazushige Kawai; Hiroaki Nozawa; Kazuhito Sasaki; Koji Murono; Soichiro Ishihara
Journal:  Int J Clin Oncol       Date:  2021-06-03       Impact factor: 3.402

3.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

4.  Lymph Node Metastases in Colon Cancer Are Polyclonal.

Authors:  Peter J Ulintz; Joel K Greenson; Rong Wu; Eric R Fearon; Karin M Hardiman
Journal:  Clin Cancer Res       Date:  2017-12-04       Impact factor: 12.531

5.  Does lateral lymph node dissection improve survival in rectal carcinoma? Examination of node metastases by the clearing method.

Authors:  J Hida; M Yasutomi; K Fujimoto; T Maruyama; K Okuno; K Shindo
Journal:  J Am Coll Surg       Date:  1997-05       Impact factor: 6.113

6.  Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.

Authors:  Soichiro Ishihara; Kazushige Kawai; Toshiaki Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Hioaki Nozawa; Teppei Morikawa; Toshiaki Watanabe
Journal:  Dis Colon Rectum       Date:  2017-05       Impact factor: 4.585

7.  Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.

Authors:  H Nagawa; T Muto; K Sunouchi; Y Higuchi; G Tsurita; T Watanabe; T Sawada
Journal:  Dis Colon Rectum       Date:  2001-09       Impact factor: 4.585

8.  Lymphatic spread and its prognostic value in patients with rectal cancer.

Authors:  K Hojo; Y Koyama; Y Moriya
Journal:  Am J Surg       Date:  1982-09       Impact factor: 2.565

9.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

10.  Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method.

Authors:  E Morikawa; M Yasutomi; K Shindou; T Matsuda; N Mori; J Hida; R Kubo; M Kitaoka; M Nakamura; K Fujimoto
Journal:  Dis Colon Rectum       Date:  1994-03       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.